RevolKa develops aiProtein®, an AI-assisted directed evolution platform that predicts and optimizes protein sequences to create novel, highly functional proteins for therapeutic and industrial use. The platform is trained on sequence–function relationship data and can evolve multiple properties simultaneously. RevolKa reports that aiProtein® has produced successful outcomes with multiple partner companies. The company is applying the technology to rare disease drug discovery and development, efforts it previously announced on July 30, 2024. RevolKa joined a four-year research program funded by the Japanese Agency for Medical Research and Development (AMED) to accelerate these efforts. The company was founded in April 2021 and is headquartered in Sendai, Japan. RevolKa develops aiProtein®, an AI-assisted protein engineering platform that designs sequences to produce proteins with desired functions and can engineer multiple properties simultaneously. The platform targets both pharmaceutical and industrial applications and has produced successful outcomes in collaborations with partner companies. The company will use the ¥210 million JPY (US$1.4M) Series A extension to advance drug discovery programs for rare diseases and to support collaborative partnering efforts. RevolKa was founded in April 2021 and is headquartered in Sendai, Japan. Investors include D3 LLC, TOHOKU University Venture Partners, DEEPCORE Inc., and SBI Investment Co., Ltd. RevolKa positions aiProtein® to address the protein sequence-to-function relationship that remains unresolved despite advances like AlphaFold. RevolKa develops aiProtein®, an AI-assisted directed evolution platform that designs and evolves high-performance proteins beyond natural evolution. The company was founded in April 2021 and is headquartered in Tokyo with laboratories in Sendai. RevolKa announced the launch of a drug discovery program for rare diseases on July 30, 2024, and reports some drug candidates have achieved positive in vitro proof-of-concept. Its technology is positioned for both pharmaceutical and industrial uses and has produced successful collaborations with partner companies. Investors include Tohoku University Venture Partners and SBI Investment, with new participation from D3 LLC and DEEPCORE. The company says recent funding will accelerate its drug discovery and development activities.

Total raised

$2M

Funding rounds

3

Latest round

Grant

Latest activity

Jun 2025